Capital Raise Sizing Calculator: How Much to Raise and What It Costs in Dilution
To size the raise, multiply monthly burn by your target runway and add your one-time uses of funds. Add a contingency buffer to that total, then gross it up for transaction costs. Dilution is the gross raise divided by the post-money value.
Here is an example. A company burns $150,000 a month, needs 18 months of runway and has $1 million of build-out to fund. Apply a 20% buffer, 4% transaction costs and a $12 million pre-money valuation. The company needs a gross raise of $4,625,000, and new investors take 27.82%. That is our arithmetic, and each step is shown below.
Data current as of November 20, 2026. Each figure names its source and as-of date: PESP 2025 deal review, Sikich Q3 2026 update (reporting PitchBook data), BuckheadFMV control transactions January 2023 to October 2026, Axia Growth closed sales as of October 28, 2026, Damodaran (NYU Stern) January 2026, Kaufman Hall Q3 2026 report dated October 13, 2026.
Estimate only. Educational, not investment advice.
The 6 inputs and where to find each number
| Input | What to enter | Where to find it | Example default |
|---|---|---|---|
| Monthly burn | Average net cash out per month, after collections | Trailing 3 to 6 months of cash flow statements, adjusted for planned hires | $150,000 |
| Runway months | Months the raise must fund before the next raise or breakeven | Operating plan. Use 18 to 24 for growth companies | 18 |
| Uses of funds | One-time spend: build-out, equipment, acquisition deposits, EHR or software build | Capex budget, vendor quotes, LOI deposits | $1,000,000 |
| Buffer % | Contingency on burn and uses only. Transaction costs are grossed up separately in the next step | Board judgment. 15% to 25% is common | 20% |
| Transaction costs % | Legal, accounting, placement, filing and diligence costs as a share of gross raise | Engagement letters and counsel estimates | 4% |
| Pre-money valuation | Equity value before new money: enterprise value less net debt and other debt-like items | Term sheet, or EBITDA times a market multiple from the tables below, then adjusted | $12,000,000 |
Owners get burn wrong more often than any other input. Use cash burn, not accounting loss. A home health or behavioral company that waits 60 to 90 days for payer collections burns more cash than its P&L shows.
The pre-money input is equity value, not enterprise value. Investors start from enterprise value and subtract net debt. In healthcare they also subtract debt-like items: accrued deferred compensation, known payer recoupments or overpayment liabilities, unpaid tax and any shortfall against a normal working-capital level. Each dollar of those items comes straight off the pre-money.
The 4% cost default is our modeling assumption, not a market statistic. Cost loads depend on deal complexity, on whether a placement agent is paid and on how much diligence the investor runs. Enter the figure from your own engagement letters. In the example, moving from 4% to 5% raises the gross raise from $4,625,000 to $4,673,684, an increase of 1.05% (our arithmetic: 0.96 ÷ 0.95 = 1.0105). Each further point adds slightly more, because the divisor shrinks.
The 6 outputs, defined exactly
| Output | Exact definition |
|---|---|
| Base need | Monthly burn × runway months + uses of funds |
| Need with buffer | Base need × (1 + buffer %) |
| Gross raise | Need with buffer ÷ (1 − transaction costs %) |
| Transaction costs | Gross raise × transaction costs % |
| Post-money valuation | Pre-money valuation + gross raise |
| Dilution | Gross raise ÷ post-money valuation, shown as a percentage |
In plain words: take burn times months, add one-time spend and add the buffer. Divide by what is left after costs, because costs come out of the money investors send. New investors own the gross raise as a share of post-money.
Which sizing method fits your business
The calculator handles both methods. What changes is which inputs carry the weight.
| Business profile | Sizing method | Runway input | Uses input | Typical buffer |
|---|---|---|---|---|
| Pre-revenue or early healthtech | Runway-led | 18 to 24 months | Product build, compliance work | 20% to 25% |
| Growth-stage services company, burning cash | Runway plus uses | 12 to 18 months | De novo sites, hires, systems | 15% to 25% |
| Cash-positive practice or ASC funding a project | Uses-led | 0 to 6 months of ramp losses | Build-out, equipment, acquisition price | 10% to 20% |
| Platform buying add-ons | Uses-led, per deal | Integration losses only | Purchase price less acquisition debt | 15% to 20% |
Buffer ranges are our planning guidance, not market statistics. Set the buffer higher when collections are slow, when payer enrollment gates revenue at a new site, or when the plan depends on one hire.
Worked example: $150,000 burn, 18 months, $12 million pre-money
This is a hypothetical multi-site specialty group building two de novo locations. Assumptions: 20% buffer, 4% costs, no debt or debt-like items, no existing option pool, no convertible notes.
| Step | Calculation | Result |
|---|---|---|
| Burn for runway | $150,000 × 18 | $2,700,000 |
| Base need | $2,700,000 + $1,000,000 uses | $3,700,000 |
| Need with buffer | $3,700,000 × 1.20 | $4,440,000 |
| Gross raise | $4,440,000 ÷ 0.96 | $4,625,000 |
| Transaction costs | $4,625,000 × 4% | $185,000 |
| Post-money | $12,000,000 + $4,625,000 | $16,625,000 |
| Dilution | $4,625,000 ÷ $16,625,000 | 27.82% |
The existing owners keep 72.18%. Costs come to $185,000, not the $177,600 you get from 4% of $4,440,000. Costs apply to every dollar raised, including the dollars raised to pay the costs.
If burn is not flat. The calculator takes one average burn figure. New sites burn more cash while credentialing and payer enrollment clear, so build a monthly cash model first and enter its average. Suppose the real curve is $200,000 a month for the first 6 months and $150,000 after that. Base need rises by $300,000 ($50,000 × 6). After the 20% buffer and the 4% gross-up, the raise grows by $375,000 (our arithmetic: $300,000 × 1.20 ÷ 0.96).
Debt or equity for each use of funds
Equity is the most expensive money a profitable healthcare business can raise. Before entering a uses figure, separate the items a lender will fund.
| Use of funds | Usually financed with | Why |
|---|---|---|
| Medical equipment | Equipment loan or lease | The asset secures the loan |
| Build-out of a leased site | Tenant improvement allowance, then term debt | Landlords and banks fund it against the lease and cash flow |
| Acquisition of a profitable practice | Senior debt sized on the target's EBITDA, plus equity for the rest | Lenders fund against acquired cash flow |
| Ramp losses at a new site | Equity or a working capital line | No collateral until collections start |
| Software or product build | Equity | Lenders rarely fund intangible build |
| Working capital for payer lag | Revolving line against receivables | Receivables secure the line |
Every dollar moved from equity to debt shrinks the gross raise. In the example, financing $600,000 of the $1,000,000 build-out with an equipment loan cuts the gross raise by $750,000 ($600,000 × 1.20 ÷ 0.96), to $3,875,000. Dilution falls from 27.82% to 24.41% ($3,875,000 ÷ $15,875,000, our arithmetic). The debt capacity calculator tests how much the cash flow supports.
How sensitive dilution is to raise size and to pre-money
Dilution equals R ÷ (P + R), where R is the gross raise and P is the pre-money. The two inputs behave differently depending on whether you measure the change in dollars or in percent. Our arithmetic, holding everything else at the base case:
| Change from base case | Raise | Pre-money | Dilution | Change |
|---|---|---|---|---|
| Base case | $4,625,000 | $12,000,000 | 27.82% | n/a |
| Raise up $1,000,000 | $5,625,000 | $12,000,000 | 31.91% | +4.10 points |
| Pre-money down $1,000,000 | $4,625,000 | $11,000,000 | 29.60% | +1.78 points |
| Raise up 10% | $5,087,500 | $12,000,000 | 29.77% | +1.95 points |
| Pre-money down 10% | $4,625,000 | $10,800,000 | 29.98% | +2.16 points |
In dollars, the raise has more effect. For small changes, a dollar added to the raise moves dilution P ÷ R times as much as a dollar taken off the pre-money. In this example that ratio is about 2.6 ($12,000,000 ÷ $4,625,000). The ratio depends on the deal. A company raising a larger amount against a smaller pre-money sees a lower ratio.
In percent, the two inputs carry equal weight. For small changes, a 1% increase in the raise and a 1% cut in the pre-money move dilution by the same proportion. The 10% rows differ slightly only because the changes are not small.
What this means for owners:
- Trim the raise in dollars. Every dollar of excess raise in this example costs about 2.6 times the ownership of a dollar of valuation given up. Cutting padding from the uses list, or financing equipment with debt, is the cheapest dilution control available.
- Test the pre-money in percent. The error band is far wider on valuation. A burn model is usually off by 10% to 20%. The indicative multiple bands below run from 5x to 13x for physician practices alone, so the multiple chosen can move the pre-money by 50% or more.
The three tables below come from different datasets with different populations. Read each one on its own terms and do not average across them.
Indicative private-market ranges, 2026. Source: Sikich, Q3 2026 US healthcare M&A update. These are Sikich's indicative EV/EBITDA bands, not medians of a defined sample.
| Segment | Indicative EV/EBITDA |
|---|---|
| Physician practice, under $1M EBITDA | 5x to 7x |
| Physician practice, $1M to $3M EBITDA | 7x to 9x |
| Physician practice, $3M to $5M EBITDA | 9x to 11x |
| Physician practice, above $5M EBITDA | 11x to 13x |
| Dental: practices / add-ons / DSO platforms | 5x to 9x / 5x to 8x / 9x to 11x |
| ASC: single-specialty / multispecialty / regional operators | 5x to 8x / 6x to 10x / 11x to 17x |
| Urgent care, under $10M revenue / $10M to $50M revenue | 3x to 7x / 6x to 11x |
| Home health and hospice, small agencies | Mid-single digits |
Sikich also reports that platforms command a four- to eight-turn premium over add-on practices by specialty, and that the median ASC multiple reached 7.9x in 2025, which it calls the highest in at least eight years.
Closed-transaction medians. Each row names its population. The figures are as reported by each provider.
| Population | Median multiple | Source |
|---|---|---|
| U.S. healthcare services control deals, Jan 2023 to Oct 2026, 68 deals with positive EBITDA | 9.6x EV/EBITDA (10.1x excluding distressed sales) | BuckheadFMV |
| Same dataset, deals above $200M | 11.2x EV/EBITDA and 1.34x EV/revenue | BuckheadFMV |
| Same dataset, ambulatory surgery centers | 12.4x EV/EBITDA and 1.24x EV/revenue | BuckheadFMV |
| Same dataset, deals below $10M | 2.8x EV/EBITDA and 0.27x EV/revenue. Many are practices bought near asset value. Not a benchmark for a practice with goodwill | BuckheadFMV |
| Closed healthcare small-business sales, under $500K SDE (n=182) | 3.4x SDE (middle half 2.7x to 4.2x) | Axia Growth, data as of Oct 28, 2026 |
| Same dataset, $500K to $1M SDE (n=42) | 3.4x SDE (middle half 2.5x to 4.4x) | Axia Growth |
| Same dataset, $2M to $3M EBITDA (n=13) | 5.1x EBITDA (middle half 3.1x to 10.9x) | Axia Growth |
| Same dataset, $5M to $10M EBITDA (n=14) | 8.8x EBITDA (middle half 3.4x to 10.7x) | Axia Growth |
| Same dataset, $10M+ EBITDA (n=17) | 12.9x EBITDA (middle half 9.4x to 18.5x) | Axia Growth |
How each dataset was built, as described by each provider:
- BuckheadFMV reports screening 187 of the 215 U.S. healthcare transactions in its research database, all announced January 1, 2023 through October 31, 2026. Each deal has a disclosed or court-approved price and target financials from SEC filings, state certificate-of-need and transaction-notice filings in 12 states, bankruptcy court sale approvals or Medicare cost reports. Only control transactions are included. EV/EBITDA appears only where EBITDA is positive. BuckheadFMV states that large and public-company deals report EBITDA far more often than small private ones, so its EBITDA medians lean toward larger transactions. Its yearly EBITDA medians ran 11.4x (2023), 9.7x (2024), 6.5x (2025) and 9.1x (2026 through October), and it attributes the 2025 dip to a smaller, more mid-market mix. It also reports that hospital purchases of individual primary care practices, largely in West Virginia, cluster at 0.05x to 0.15x revenue, which explains the low below-$10M median. These are small samples from one provider, and the methodology is on its page.
- Axia Growth reports analyzing 4,554 closed small-business sales over $500K, aggregated and de-identified. The healthcare rows above are a subset. The lower bands use seller's discretionary earnings (SDE), which adds back owner pay, so an SDE multiple is not comparable to an EBITDA multiple. Sample sizes above $2M are small and the middle-half ranges are wide.
Reconciling the ASC figures. BuckheadFMV's 12.4x ASC median and Sikich's 5x to 8x single-specialty band describe different deals. BuckheadFMV's ASC median draws on control deals with disclosed EBITDA, which skew larger. That places it inside Sikich's 11x to 17x band for regional operators. A single-specialty center raising equity should anchor to Sikich's 5x to 8x band and the 7.9x 2025 median.
Public-company multiples, U.S., January 2026. Source: Damodaran, NYU Stern, EV/EBITDA and EV/Sales datasets.
| Sector | Firms | EV/EBITDA | EV/Sales |
|---|---|---|---|
| Healthcare information and technology | 115 | 21.27x | 5.31x |
| Healthcare products | 204 | 19.78x | 4.76x |
| Drugs (pharmaceutical) | 228 | 15.25x | 6.24x |
| Healthcare support services | 104 | 11.17x | 0.46x |
| Hospitals and healthcare facilities | 31 | 8.86x | 1.69x |
| Total market excluding financials | 4,822 | 16.95x | n/a |
The two columns come from separate Damodaran files that aggregate differently, so dividing EV/Sales by EV/EBITDA does not give a reliable sector EBITDA margin. Public multiples reflect liquid, scaled companies. They are an upper reference for private healthtech, not a target.
Worked check on the example. At 8x, the midpoint of Sikich's $1 million to $3 million practice band, a $12 million pre-money implies $1.5 million of EBITDA. That holds only if enterprise value equals equity value, which means no debt, no debt-like items and no excess cash. Adjustments move the figure (our arithmetic, same $4,625,000 raise):
| Scenario | Pre-money (equity value) | Post-money | Dilution |
|---|---|---|---|
| $1.5M EBITDA × 8x, no debt or cash | $12,000,000 | $16,625,000 | 27.82% |
| $1.5M EBITDA × 8x, $2M net debt and debt-like items | $10,000,000 | $14,625,000 | 31.62% |
| $900K EBITDA × 8x, no debt or cash | $7,200,000 | $11,825,000 | 39.11% |
The $900K row applies 8x for comparison only. Sikich's band for practices under $1 million of EBITDA is 5x to 7x, so the real pre-money would likely come in lower.
Market-level pricing has also come down. PitchBook data reported in Sikich's Q3 2026 update puts the median healthcare M&A multiple at 14.5x EV/EBITDA in 2024, 13x in 2025 and 11.6x for 2026 year to date through the third quarter. The same data puts the median PE-backed healthcare services buyout at 13.6x EBITDA in 2025, against 13.5x in 2024, with implied target EBITDA of roughly $33 million. Those medians cover larger deals across all of healthcare. They are not practice-level figures. The direction still matters: a pre-money anchored to 2024 comps overstates 2026 pricing. The healthcare valuation multiples guide breaks this out by segment.
Staging the raise: two rounds versus one
Price is the other lever on dilution, and price rises when the company hits milestones. The tables below compare one round against two rounds that deliver the same $4,440,000 of buffered net cash.
Assumptions (our arithmetic):
- Round 1. $2,000,000 gross at 4% costs nets $1,920,000.
- Round 2. Round 2 must net the remaining $2,520,000. It carries 4% costs plus an assumed $75,000 of fixed legal, accounting and diligence costs that a second process repeats. That makes the gross raise ($2,520,000 + $75,000) ÷ 0.96 = $2,703,125. Replace the $75,000 with your own counsel's estimate.
- Totals. Staged gross raise is $4,703,125 against $4,625,000 for one round. Total costs are $263,125 against $185,000.
- Ownership. There is no option pool, note or other security. Each round dilutes all prior holders pro rata, so combined retention is Round 1 retention × Round 2 retention. The Round 2 pre-money is a hypothetical input.
| Hypothetical | Gross raise | Pre-money | Round dilution | Owners retain |
|---|---|---|---|---|
| One round today | $4,625,000 | $12,000,000 | 27.82% | 72.18% |
| Round 1 today | $2,000,000 | $12,000,000 | 14.29% | 85.71% |
| Round 2 after milestone | $2,703,125 | $20,000,000 | 11.91% | 88.09% |
| Two rounds combined | $4,703,125 | n/a | 24.49% | 75.51% (85.71% × 88.09%) |
Staging saves 3.33 points only if the step-up arrives. Run the Round 2 price as a scenario before committing:
| Round 2 pre-money | Round 2 dilution | Owners retain after both rounds | vs. one round |
|---|---|---|---|
| $12,000,000 (down) | 18.38% | 69.96% | 2.22 points worse |
| $14,000,000 (equal to Round 1 post) | 16.18% | 71.84% | 0.34 points worse |
| About $14,420,000 | 15.79% | 72.18% | Breakeven |
| $16,000,000 | 14.45% | 73.33% | 1.15 points better |
| $20,000,000 | 11.91% | 75.51% | 3.33 points better |
The breakeven rule follows from the table. Without repeated fixed costs, staging breaks even when Round 2 prices exactly at Round 1's post-money, here $14 million. The $75,000 second-process cost pushes breakeven to about $14.42 million. Staging has to clear Round 1's post-money by enough to pay for the second process.
The cash clock is the real risk. Round 1 nets $1,920,000. If it funds one de novo site at $500,000, $1,420,000 remains. At $150,000 a month that lasts about 9.5 months. Round 2 has to close inside that window, after the milestone is visible, so the process starts around month 4 or 5. A milestone that slips by one quarter leaves the company raising from a weak position.
Build process time into the inputs. Set Round 1's runway to the months to milestone plus the months a raise takes, then rerun. Take a 6-month milestone plus a 6-month raise, which means 12 months of runway. Round 1 then needs $150,000 × 12 + $500,000 = $2,300,000, or $2,875,000 after a 20% buffer and 4% gross-up. That is $875,000 more than the $2 million in the table, at 19.33% dilution instead of 14.29% ($2,875,000 ÷ $14,875,000, our arithmetic).
The milestone has to be one an investor will pay for:
| Milestone | Why investors pay for it | Evidence to show at Round 2 |
|---|---|---|
| Second site at cash breakeven | Proves the de novo model repeats | Monthly site P&L, payer mix, collections lag |
| Signed payer contract | Locks in rate and volume | Executed contract, rate schedule, enrollment status |
| Closed add-on acquisition | Adds EBITDA that moves the multiple band | Closing financials, quality of earnings |
| Recurring revenue threshold (healthtech) | Lowers risk on the revenue model | Cohort retention, contracted backlog |
Size the first close to what the current investor pipeline can fund in 90 to 120 days. A $10 million target that the company's traction cannot support stays open for months, and investors read that as other investors passing. Size the target to the investors who have already asked for diligence materials, and have those materials ready using the healthcare data room checklist.
Where healthcare capital went in 2025
| Deal type, PE-backed healthcare, 2025 | Count | Share (our arithmetic) |
|---|---|---|
| Add-on acquisitions | 664 | 64.5% |
| Growth investments | 214 | 20.8% |
| Leveraged buyouts | 151 | 14.7% |
| Total | 1,029 | 100% |
Source: Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review, drawn from PitchBook and LevinPro HC. The deals involved 420 platform companies and 708 investment firms. PESP says its final count is likely an underestimate.
Growth investments were about one deal in five by count. The busiest subsectors in the PESP data were health IT (151 deals), dental (149), outpatient care (148), medtech (117) and behavioral health (56). The mix matters for sizing:
- Dental. PESP reports that 95% of 2025 dental deals were add-ons by PE-owned platforms. Ten of the 18 platforms with the most deals were dental companies. A dental owner raising minority growth money competes for attention with buyers who would rather acquire the practice outright.
- Outpatient. 119 of the 148 outpatient deals were add-ons, about 80% (our arithmetic). Dermatology led with 24 deals, then eye care with 22 and oncology with 9. Those figures are PESP data reported by Becker's ASC Review.
- Hospitals. Kaufman Hall's Q3 2026 report (October 13, 2026) counted 16 hospital and health system transactions in the quarter, matching Q3 2025, with $8.2 billion of transacted revenue and an average seller size near $586 million. Divestitures made up nearly one-third of the deals. Becker's Hospital Review, reporting Kaufman Hall data, puts the 2026 total at 56 through the third quarter. That compares with 46 in all of 2025, the lowest annual count since tracking began in 2011. Kaufman Hall found nearly 43% of hospitals operating at a loss on year-to-date data through August 2026. Capital in that segment moves mainly through mergers and divestitures rather than growth rounds.
Reading the dilution number without freezing
Some owners see 27.82% and walk away. The right test is value after the raise, not the ownership percentage. Two hypotheticals on the worked example (our arithmetic):
| Outcome after the raise | Company equity value | Owners' 72.18% is worth | vs. $12M today |
|---|---|---|---|
| Raise funds growth | $25,000,000 | About $18,045,000 | +$6,045,000 |
| Raise funds survival, value flat at post-money | $16,625,000 | About $12,000,000 | No gain |
In the second case the dilution bought nothing. The raise has to fund something that grows equity value faster than it dilutes the owners.
3 ways the result goes wrong in real deals
- The pre-money ignores debt and debt-like items. Investors price enterprise value and subtract net debt, deferred compensation, payer recoupment exposure and any working-capital shortfall. In the example, $2 million of those items moves dilution from 27.82% to 31.62%.
- Burn leaves out ramp and reimbursement lag. A flat average understates the early months of a new site. The ramp case above adds $375,000 to the raise.
- Term sheet terms raise effective dilution. The option pool basis decides who pays for the pool. Assume no existing pool and a new pool equal to 10% of post-money (our arithmetic):
| Pool convention | Investors | Option pool | Existing owners |
|---|---|---|---|
| No pool | 27.82% | 0% | 72.18% |
| 10% of post-money, carved from the pre-money | 27.82% | 10.00% | 62.18% |
| 10% created after the round, all holders diluted pro rata | 25.04% | 10.00% | 64.96% |
Under the pre-money convention, the investors' 27.82% stays fixed and the full pool comes out of the owners' share. Notes and SAFEs that convert at a discount add more dilution. Liquidation preferences do not change ownership, but they shift exit proceeds to the new money. Run each clause through the LOI and term sheet red flags checklist.
The sizing pack to finish before the first investor meeting
Investors test the raise amount before they test the pitch. A number backed by these eight documents holds up in diligence. A number typed straight into the calculator does not. Each row shows the figure from the worked example that the document has to support.
| Document | What it proves | Figure it supports in the example |
|---|---|---|
| Monthly cash model, 18 months, with a ramp case | Burn is cash, not accounting loss, and the ramp is priced | $150,000 average burn, ramp case adds $375,000 to the raise |
| Uses of funds schedule, split into debt and equity | Only the uses lenders will not fund are in the equity raise | $1,000,000 uses, moving $600,000 to an equipment loan cuts the raise to $3,875,000 |
| Enterprise value to equity value bridge | The pre-money already nets out debt and debt-like items | $1.5M EBITDA × 8x = $12,000,000, $2M of debt-like items takes it to $10,000,000 |
| Comparable multiple memo | The multiple matches the right segment and size band | 8x, the midpoint of Sikich's $1M to $3M practice band |
| Cost estimate from engagement letters | The gross-up uses real quotes, not a default | 4% = $185,000, 5% raises the gross raise to $4,673,684 |
| Pro forma cap table under each pool convention | Owners know their retained stake before the term sheet arrives | 72.18% with no pool, 62.18% or 64.96% with a 10% pool |
| One-round versus staged comparison | The board has seen the breakeven price for Round 2 | Breakeven at about $14.42 million Round 2 pre-money |
| Cash-out date and milestone evidence list | Round 2 can close before cash runs out | Round 1 cash lasts about 9.5 months after one de novo site |
Two checks before the pack goes out:
- Reconcile the totals. Base need, buffer, gross-up and costs in the pack must tie to the calculator output to the dollar. In the example that means $3,700,000, $4,440,000, $4,625,000 and $185,000.
- Rerun at the low end. Enter the low end of the multiple band and the ramp-case burn together. If dilution at that combination is one the owners would refuse, cut the uses list or move more of it to debt before the first meeting, not after.
Who invests, who is paid to find investors and how a clinical business is owned can each change the structure behind these numbers. Take those questions to your own attorney, starting from our guides on securities rules for raising capital, physician investors who refer and who can be paid to introduce investors.
What to do after you run the numbers
- Test the pre-money. Run the practice valuation calculator on trailing EBITDA, subtract net debt and debt-like items, and compare the result to the pre-money you entered.
- Price debt against equity. If the uses of funds are equipment or build-out, the debt capacity calculator shows how much of the $1 million could be financed without dilution.
- Map the capital stack. The healthcare capital stack infographic shows which investor types fund which layer and at what cost.
- Pick the investor pool. The capital raising guide for healthcare companies covers sources, terms and what each investor type expects.
- Bring three scenarios to the board. First, one round at today's price. Second, a staged raise with Round 1 runway set to milestone months plus raise months and Round 2 costs that include the repeated fixed costs. Third, the same staged raise with Round 2 priced at Round 1's post-money.
Questions owners ask
How many months of runway should a healthcare company raise for?
Most growth-stage raises target 18 to 24 months. That covers the build plus the time a company needs to run its next raise or reach cash flow breakeven. Practices and service businesses with positive cash flow need less runway. They should size the raise around specific uses such as a de novo site, an acquisition or equipment. Pre-revenue healthtech needs the longer end because reimbursement and sales cycles run slow.
Should transaction costs be calculated on the net or the gross raise?
On the gross raise. Legal, accounting, placement and filing costs come out of the dollars investors wire, so the company needs to raise more than its net need. The calculator grosses up by dividing the buffered need by one minus the cost percentage. A 4% cost load on a $4,440,000 need produces a $4,625,000 gross raise. Adding 4% on top instead gives $4,617,600. That nets $4,432,896 after costs and leaves the company $7,104 short. The gap widens at higher cost rates.
Is the dilution percentage what founders actually give up?
It is the headline dilution from new money alone. Effective dilution runs higher when investors require an option pool carved from the pre-money or when convertible notes or SAFEs convert at a discount. Liquidation preferences leave ownership unchanged but push value to the new shares on a modest exit. Model each of those against the term sheet before treating the calculator's figure as final.
Is it better to raise less now and more later?
Only if the company hits a milestone that lifts the next round's pre-money far enough above the current round's post-money to pay for the second process. In the worked example, Round 1 is $2,000,000 at $12 million pre-money. Round 2 must net $2,520,000 and carries 4% costs plus an assumed $75,000 of repeated fixed costs, so it raises $2,703,125. On those assumptions, staging beats a single round only if Round 2 prices above about $14.42 million pre-money. At $20 million the owners keep 75.51% instead of 72.18%. At $12 million they keep 69.96%.
Sources
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, outpatient specialties in 2025 deal activity (PESP data)
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook (reporting PitchBook data)
- BuckheadFMV, Healthcare Services M&A Valuation Multiples, January 2023 to October 2026 (187 control transactions, methodology on page)
- Axia Growth, Physician Practice Management and MSOs, closed-sale data as of October 28, 2026
- Aswath Damodaran, NYU Stern, EV/EBITDA by sector (US), January 2026
- Aswath Damodaran, NYU Stern, Price and EV to Sales by sector (US), January 2026
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report, October 13, 2026
- Becker's Hospital Review, hospital M&A through Q3 2026 (Kaufman Hall data)